Olmesartan

Class
Antihypertensives
Subclass
Angiotensin receptor blockers
Substance name
Olmesartan medoxomil
Brand names
Benicar®
Common formulations
Film-coated tablet
Contained in
Olmesartan / amlodipine / hydrochlorothiazide (Tribenzor®)
Olmesartan / hydrochlorothiazide (Benicar HCT®)
Dosage and administration
Adults patients
Treatment of hypertension
•
Maintenance: 20 mg PO daily
•
Maximum: 40 mg per day
Other off-label uses
•
Prevention of migraine attacks
Indications for use
Labeled indications
Adults
•
Treatment of hypertension
Children
•
Treatment of hypertension (in patients 6-16 years)
Off-label indications
Adults
•
Prevention of migraine attacks
Safety risks
Boxed warnings
Fetal toxicity
•
Do not use in pregnant patients. Discontinue olmesartan as soon as possible when pregnancy is detected.
Contraindications
Hypersensitivity to olmesartan or its components
Concomitant use of aliskiren in patients with diabetes
Warnings and precautions
Hypotension
•
Use caution in patients with volume or salt depletion, including receiving high doses of diuretics.
Increased serum potassium
•
Use caution in patients with renal impairment, diabetes mellitus, or taking potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes. Monitor serum potassium levels regulalry.
Sprue-like enteropathy
•
Maintain a high level of suspicion, as an increased incidence has been reported in patients receiving olmesartan.
Specific populations
Renal impairment
CrCl ≥ 40 mL/min
•
Use acceptable. No dose adjustment required. Monitor renal function. Monitor for hyperkalemia.
CrCl < 40 mL/min
•
No initial adjustment required. Monitor renal function. Monitor for hyperkalemia.
Renal replacement therapy
Continuous renal replacement
•
No guidance available. Monitor renal function. Monitor for hyperkalemia.
Intermittent hemodialysis
•
No guidance available. Monitor renal function. Monitor for hyperkalemia.
Peritoneal dialysis
•
No guidance available. Monitor renal function. Monitor for hyperkalemia.
Hepatic impairment
Child-Pugh A (mild)
•
Use acceptable. No dose adjustment required.
Child-Pugh B (moderate)
•
No initial adjustment required.
Child-Pugh C (severe)
•
No initial adjustment required.
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: D
•
Do not use. Evidence of fetal harm in humans. Discontinue olmesartan when pregnancy is detected.
•
Use of RAAS inhibitors during the second and third trimesters can cause reduced fetal renal function leading to anuria and renal failure, oligohydramnios, fetal lung hypoplasia, and skeletal deformations, including skull hypoplasia, hypotension, and death.
Breastfeeding
Do not use during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Common 1-10%
•
↑ blood glucose, ↑ serum triglycerides, back pain, ↑ serum CK, diarrhea, dizziness, flu-like symptoms, pharyngitis, rhinitis, headache, hematuria
Uncommon < 1%
•
↑ liver enzymes, ↑ serum cholesterol, ↑ serum potassium, ↑ serum uric acid, peripheral edema, abdominal pain, arthralgia, asthenia, chest pain, dyspepsia, myalgia, nausea, skin rash, vertigo, vomiting, pruritus, ↑ serum TBIL, hair loss, facial edema, tachycardia
Unknown frequency
•
Anaphylaxis, angioedema, hypotension, orthostatic hypotension, renal failure, weight loss, rhabdomyolysis, sprue-like enteropathy
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource